my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-02-2008: Invitrogen Corporation (IVGN) and Agilent Technologies have jointly announced a confidential settlement of multiple patent litigations pending between the two companies. The settlement resolves three patent infringement lawsuits between Invitrogen and Stratagene Inc. Agilent acquired Stratagene in 2007.
These patent litigations between the companies had been pending since 2000 and 2001. In June 2000, Invitrogen sued Stratagene in the United States District Court for the District of Maryland, Southern Division, for infringement of Invitrogen's U.S. Patent Nos. 6,063,608, 5,244,797 and 5,405,776 relating to the use and sale of RNase H minus reverse transcriptase (RT) products. This case had been stayed pending resolution of a related litigation with Clontech.
On March 12, 2001, Invitrogen filed suit against Stratagene for infringement of U.S. Patent No. 4,981,797. That patent covers a process for producing E. coli cells that are more effective at absorbing foreign DNA and thereby more "competent." In 2006, the United States District Court for the Western District of Texas, Austin Division, entered judgment awarding Invitrogen $16.2 million plus prejudgment interest, post-judgment interest, attorneys' fees and costs, and entered an injunction against further infringement. Stratagene appealed the judgment to the United States Court of Appeals for the Federal Circuit.
In November 2001, Stratagene filed suit against Invitrogen in the United States District Court for the District of Maryland, Southern Division, for infringement of U.S. Patent No. 5,556,772 related to the use and sale of certain DNA polymerase blend products. The case had been stayed by the Court pending a reissuance proceeding before the United States Patent Office.
Under the terms of the agreement, Agilent will make an undisclosed settlement payment to Invitrogen. In addition, Agilent will discontinue sales of its RNase H minus RT products and Invitrogen will obtain a license from Agilent and pay an undisclosed royalty to sell its DNA polymerase blend products. All litigation will be dismissed. No other details of the settlement were disclosed.
Watchlist
This is where you can add this news to your personal favourites
Agilent Technologies Inc. opened a new Customer Applications and Training Center in South Korea, showcasing its latest bio-analytical instruments. The company’s goal is to collaborate with customers to develop new applications and methodologies for research in the agriculture, environment a ... more
Agilent Technologies Secures Patent for CGH Assays
Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research. The U.S. patent (No. 8,232,055) has claims for measuring copy number change ... more
Agilent to Acquire Dako for $2.2 Billion
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In ... more
Half a Century of Chromatography with Agilent and Predecessors
Twsett originated the chromatography with his work about the separation of chlorophyll in 1903. For some time it was relatively quite around this new technology. Exceptions were the workings of Kuhn and Lederer (1931) as well as of Hesse (1936 and 1942). A break through succeeded to E. Crem ... more
Agilent Technologies Sales & Services GmbH & Co. KG
Agilent T. is a global diversified technology company that serves markets that include communications, electronics and life sciences. more
Invitrogen Announces Opening of Hepatocyte Supply Facility in Warrington, UK
Invitrogen, part of Life Technologies Corporation, announced the opening of a new facility in Warrington, UK, which will supply freshly isolated human hepatocytes to researchers in Europe. Human hepatocytes isolated from liver tissue are used for many biopharmaceutical applications, by res ... more
Invitrogen and Applied Biosystems Complete Merger
Invitrogen Corporation and Applied Biosystems Inc. announced the successful completion of their merger transaction. The new company will be named Life Technologies Corporation and is traded on the NASDAQ Global Select Market under the ticker symbol "LIFE" beginning November 24, 2008. “Thi ... more
Invitrogen, Agilent Technologies Settle Multiple Patent Litigations
Invitrogen Corporation (IVGN) and Agilent Technologies have jointly announced a confidential settlement of multiple patent litigations pending between the two companies. The settlement resolves three patent infringement lawsuits between Invitrogen and Stratagene Inc. Agilent acquired Strata ... more
Invitrogen Corporation is a global company with revenues of $1.15 billion. We provide products and services to pharmaceutical and biotechnology companies, as well as academic and government research institutions. More than 4,300 employees work for Invitrogen and we conduct business in over ... more
Invitrogen is a key partner in the global life science community. We provide products and services that support academic and government research institutions as well as pharmaceutical and biotechnology companies. more
Invitrogen Corporation is a global company with revenues of $1.15 billion. We provide products and services to pharmaceutical and biotechnology companies, as well as academic and government research institutions. More than 4,300 employees work for Invitrogen and we conduct business in over ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
